한빛사 논문
- 조회405
Heon Seok Kim 1,2,3, Susan M. Grimes 1, Tianqi Chen 1, Anuja Sathe 1, Billy T. Lau 1, Gue-Ho Hwang 4, Sangsu Bae 4,5 & Hanlee P. Ji 1,6,*
1Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
2Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea.
3Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Republic of Korea.
4Medical Research Center of Genomic Medicine Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
5Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, Republic of Korea.
6Department of Electrical Engineering, Stanford University, Stanford, CA, USA.
*Corresponding author: correspondence to Hanlee P. Ji
Abstract
Genome sequencing studies have identified numerous cancer mutations across a wide spectrum of tumor types, but determining the phenotypic consequence of these mutations remains a challenge. Here, we developed a high-throughput, multiplexed single-cell technology called TISCC-seq to engineer predesignated mutations in cells using CRISPR base editors, directly delineate their genotype among individual cells and determine each mutation’s transcriptional phenotype. Long-read sequencing of the target gene’s transcript identifies the engineered mutations, and the transcriptome profile from the same set of cells is simultaneously analyzed by short-read sequencing. Through integration, we determine the mutations’ genotype and expression phenotype at single-cell resolution. Using cell lines, we engineer and evaluate the impact of >100 TP53 mutations on gene expression. Based on the single-cell gene expression, we classify the mutations as having a functionally significant phenotype.
논문정보
- Research article
- 2023년 09월 (BRIC 등록일 2023-09-12)
- 국내+국외 연구진
- 생명과학 > 유전학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
